Insider · CIK 0001960780
Raymond M Jordt
Files at ALT (Altimmune, Inc.). First filing -, latest -.
Raymond M Jordt files SEC Form 4 as officer at ALT (Altimmune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Raymond M Jordt has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | ALT Altimmune, Inc. | AGrant or award Common Stock, par value $0.0001 | +4,571 | $3.07 | $14k | 70,107 | Feb 2, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +15,850 | $0.00 | $0 | 69,765 | Jan 29, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -4,229 | $6.18 | $26k | 65,536 | Jan 29, 2026 |
| Jan 27, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -15,850 | $0.00 | $0 | 47,550 | Jan 29, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +14,600 | $0.00 | $0 | 57,770 | Jan 27, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -3,855 | $5.50 | $21k | 53,915 | Jan 27, 2026 |
| Jan 25, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -14,600 | $0.00 | $0 | 29,200 | Jan 27, 2026 |
| Jan 1, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +9,375 | $0.00 | $0 | 45,645 | Jan 5, 2026 |
| Jan 1, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -2,475 | $3.61 | $8,935 | 43,170 | Jan 5, 2026 |
| Jan 1, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,375 | $0.00 | $0 | 9,375 | Jan 5, 2026 |
| Jul 31, 2025 | ALT Altimmune, Inc. | AGrant or award Common Stock, par value $0.0001 | +1,368 | $3.14 | $4,296 | 36,270 | Aug 4, 2025 |
| Jan 31, 2025 | ALT Altimmune, Inc. | AGrant or award Common Stock, par value $0.0001 | +2,614 | $5.18 | $14k | 34,902 | Feb 3, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +14,600 | $0.00 | $0 | 36,150 | Jan 28, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -3,862 | $6.98 | $27k | 32,288 | Jan 28, 2025 |
| Jan 25, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | +14,600 | $0.00 | $0 | 43,800 | Jan 28, 2025 |
| Jan 27, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +183,600 | $0.00 | $0 | 183,600 | Jan 28, 2025 |
| Jan 27, 2025 | ALT Altimmune, Inc. | AGrant or award Restricted Stock Unitsderivative | +63,400 | $0.00 | $0 | 63,400 | Jan 28, 2025 |
| Jan 1, 2025 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +9,375 | $0.00 | $0 | 24,035 | Jan 3, 2025 |
| Jan 1, 2025 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -2,485 | $7.21 | $18k | 21,550 | Jan 3, 2025 |
| Jan 1, 2025 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,375 | $0.00 | $0 | 18,750 | Jan 3, 2025 |
Questions about Raymond M Jordt
Answered from the filings on this page, as of the latest one.
Is Raymond M Jordt buying or selling?
Raymond M Jordt has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Raymond M Jordt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Raymond M Jordt has 0.
Where does Raymond M Jordt file Form 4?
Raymond M Jordt has filed Form 4 at ALT (Altimmune, Inc.) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.